Syneos Health - SYNH Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $56.90
  • Forecasted Upside: 69.40 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$33.59
▼ -0.35 (-1.03%)

This chart shows the closing price for SYNH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Syneos Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYNH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYNH

Analyst Price Target is $56.90
▲ +69.40% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Syneos Health in the last 3 months. The average price target is $56.90, with a high forecast of $81.00 and a low forecast of $30.00. The average price target represents a 69.40% upside from the last price of $33.59.

This chart shows the closing price for SYNH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 10 investment analysts is to hold stock in Syneos Health. This rating has held steady since September 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/6/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/3/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/3/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/1/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/29/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2022Deutsche Bank AktiengesellschaftLower Target$77.00 ➝ $51.00Low
11/7/2022Robert W. BairdLower TargetOutperform$80.00 ➝ $42.00Low
11/6/2022BarclaysLower TargetOverweight$60.00 ➝ $30.00Low
11/6/2022CitigroupLower TargetNeutral$55.00 ➝ $30.00Low
10/18/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$85.00 ➝ $53.00N/A
10/12/2022Deutsche Bank AktiengesellschaftLower TargetBuy$99.00 ➝ $77.00Low
10/12/2022MizuhoLower TargetBuy$87.00 ➝ $66.00Low
10/6/2022BarclaysLower TargetOverweight$70.00 ➝ $60.00Low
10/5/2022CitigroupLower TargetNeutral$70.00 ➝ $55.00Low
9/16/2022Robert W. BairdLower TargetOutperform$89.00 ➝ $80.00Low
9/14/2022GuggenheimDowngradeBuy ➝ NeutralLow
9/12/2022BarclaysLower TargetOverweight$80.00 ➝ $70.00Low
9/7/2022UBS GroupInitiated CoverageNeutral$68.00Low
8/9/2022Evercore ISILower Target$73.00Low
8/9/2022Robert W. BairdLower Target$89.00Low
8/3/2022MizuhoLower TargetBuy$94.00 ➝ $87.00N/A
8/3/2022BarclaysLower Target$90.00 ➝ $80.00Low
8/3/2022Robert W. BairdLower Target$99.00 ➝ $89.00Low
8/3/2022CitigroupLower Target$80.00 ➝ $70.00Low
8/3/2022William BlairDowngradeOutperform ➝ Market PerformLow
7/13/2022BarclaysLower TargetOverweight$95.00 ➝ $90.00N/A
5/23/2022GuggenheimInitiated CoverageBuy$81.00Medium
5/20/2022MizuhoReiterated RatingBuy$94.00Low
4/25/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$101.00 ➝ $75.00High
4/11/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$102.00Medium
3/7/2022MizuhoLower TargetBuy$109.00 ➝ $94.00High
1/27/2022BarclaysLower TargetOverweight$115.00 ➝ $105.00Low
12/15/2021CitigroupDowngradeBuy ➝ Neutral$115.00 ➝ $105.00High
11/4/2021Robert W. BairdBoost TargetPositive ➝ Outperform$115.00 ➝ $122.00High
11/4/2021BarclaysUpgradeEqual Weight ➝ Overweight$98.00 ➝ $115.00High
11/4/2021KeyCorpBoost TargetOverweight$100.00 ➝ $105.00High
8/5/2021Credit Suisse GroupBoost TargetOutperform$96.00 ➝ $100.00High
7/13/2021BarclaysBoost TargetEqual Weight$90.00 ➝ $102.00Low
4/30/2021MizuhoBoost TargetBuy$82.00 ➝ $90.00Medium
3/8/2021BarclaysInitiated CoverageEqual Weight$84.00N/A
3/8/2021KeyCorpBoost TargetOverweight$76.00 ➝ $90.00Medium
3/2/2021BarclaysInitiated CoverageEqual Weight$84.00Medium
2/22/2021MizuhoBoost TargetBuy$72.00 ➝ $87.00Medium
2/19/2021CitigroupBoost Target$80.00 ➝ $85.00Low
12/9/2020JPMorgan Chase & Co.Boost TargetOverweight$80.00 ➝ $85.00Low
12/9/2020Smith Barney CitigroupBoost Target$75.00 ➝ $80.00Low
12/9/2020MizuhoBoost TargetPositive ➝ Buy$65.00 ➝ $72.00Low
12/7/2020Credit Suisse GroupBoost TargetOutperform$72.00 ➝ $75.00Medium
10/6/2020MizuhoUpgradeNeutral ➝ Buy$63.00 ➝ $65.00Low
10/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$69.00 ➝ $75.00High
8/12/2020Truist FinancialBoost TargetBuy$74.00 ➝ $80.00Medium
8/7/2020CitigroupBoost TargetBuy$70.00 ➝ $75.00Low
8/7/2020MizuhoBoost TargetNeutral$50.00 ➝ $63.00Low
7/16/2020SunTrust BanksBoost TargetBuy$66.00 ➝ $74.00Low
5/1/2020SunTrust BanksBoost TargetBuy$56.00 ➝ $66.00Medium
4/30/2020CfraBoost TargetBuy$55.00 ➝ $61.00Medium
4/28/2020UBS GroupLower TargetNeutral$74.00 ➝ $58.00High
4/9/2020CitigroupLower TargetBuy$85.00 ➝ $65.00High
4/3/2020MizuhoLower TargetNeutral$56.00 ➝ $42.00Medium
4/2/2020Credit Suisse GroupLower TargetOutperform$72.00 ➝ $62.00High
3/30/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$79.00 ➝ $45.00High
3/26/2020BarclaysLower TargetEqual Weight$67.00 ➝ $61.00Medium
3/23/2020Jefferies Financial GroupLower TargetBuy$80.00 ➝ $52.00Medium
3/17/2020SunTrust BanksLower TargetBuy$80.00 ➝ $58.00Low
2/23/2020BarclaysReiterated RatingHold$67.00High
2/21/2020Credit Suisse GroupBoost TargetOutperform$68.00 ➝ $72.00Low
2/21/2020Robert W. BairdBoost TargetOutperform$74.00 ➝ $82.00Low
2/21/2020UBS GroupBoost TargetNeutral$62.00 ➝ $74.00Low
2/21/2020MizuhoBoost TargetNeutral$52.00 ➝ $67.00Low
1/21/2020Credit Suisse GroupReiterated RatingBuy$68.00Low
1/16/2020Robert W. BairdBoost TargetOutperform$62.00 ➝ $74.00Medium
1/16/2020KeyCorpBoost TargetOverweight$65.00 ➝ $71.00Medium
1/6/2020CitigroupInitiated CoverageBuy$75.00Low
9/23/2019Jefferies Financial GroupBoost TargetBuy$62.00 ➝ $65.00Low
9/3/2019KeyCorpBoost TargetOverweight$63.00 ➝ $65.00Low
8/29/2019UBS GroupBoost TargetNeutral$53.50 ➝ $57.00Low
8/23/2019Credit Suisse GroupBoost TargetOutperform$56.00 ➝ $58.00High
8/8/2019KeyCorpBoost TargetOverweight$59.00 ➝ $63.00Low
8/7/2019SunTrust BanksBoost TargetBuy$68.00Low
4/17/2019BarclaysReiterated RatingHold$48.00High
4/2/2019Wolfe ResearchInitiated CoverageMarket PerformMedium
3/19/2019UBS GroupDowngradeBuy ➝ Neutral$55.00Low
3/19/2019Credit Suisse GroupBoost TargetOutperform ➝ Outperform$49.00 ➝ $51.00Low
3/19/2019William BlairReiterated RatingOutperformMedium
1/8/2019Robert W. BairdSet TargetBuy$60.00Low
1/3/2019BarclaysLower TargetEqual Weight ➝ Equal Weight$51.00 ➝ $45.00Low
12/19/2018SunTrust BanksLower TargetBuy$55.00Low
10/19/2018William BlairUpgradeMarket Perform ➝ OutperformLow
10/9/2018UBS GroupInitiated CoverageBuy ➝ Buy$60.00Low
10/4/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$58.00High
8/10/2018KeyCorpBoost TargetOverweight ➝ Overweight$54.00 ➝ $59.00Low
8/6/2018MizuhoReiterated RatingHold$51.00High
8/3/2018SunTrust BanksReiterated RatingBuy$60.00Low
8/3/2018BarclaysReiterated RatingEqual Weight ➝ Hold$43.00 ➝ $51.00Medium
4/20/2018Mitsubishi UFJ Financial GroupInitiated CoverageOverweight$50.00Low
3/1/2018BarclaysReiterated RatingEqual Weight ➝ Equal Weight$40.00 ➝ $43.00Low
3/1/2018SunTrust BanksBoost TargetBuy$55.00Low
2/26/2018KeyCorpReiterated RatingOverweight ➝ Overweight$50.00 ➝ $46.00Low
2/23/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
2/22/2018Robert W. BairdSet TargetBuy$50.00High
1/4/2018Credit Suisse GroupReiterated RatingBuy$52.00Medium
1/4/2018KeyCorpReiterated RatingBuy$50.00Medium
12/11/2017BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$40.00High
12/1/2017SunTrust BanksLower TargetBuy$50.00Medium
12/1/2017MizuhoSet TargetNeutral ➝ Neutral$57.00 ➝ $41.00Medium
(Data available from 11/28/2017 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/2/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/1/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/31/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/30/2022
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/29/2022
  • 11 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/29/2022
  • 4 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/28/2022

Current Sentiment

  • 4 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Syneos Health logo
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $33.59
Low: $33.26
High: $34.50

50 Day Range

MA: $42.99
Low: $25.70
High: $51.45

52 Week Range

Now: $33.59
Low: $22.89
High: $104.17

Volume

997,789 shs

Average Volume

803,844 shs

Market Capitalization

$3.46 billion

P/E Ratio

12.21

Dividend Yield

N/A

Beta

1.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Syneos Health?

The following equities research analysts have issued reports on Syneos Health in the last year: Barclays PLC, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Robert W. Baird, StockNews.com, TheStreet, UBS Group AG, and William Blair.
View the latest analyst ratings for SYNH.

What is the current price target for Syneos Health?

10 Wall Street analysts have set twelve-month price targets for Syneos Health in the last year. Their average twelve-month price target is $56.90, suggesting a possible upside of 69.4%. Guggenheim has the highest price target set, predicting SYNH will reach $81.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $30.00 for Syneos Health in the next year.
View the latest price targets for SYNH.

What is the current consensus analyst rating for Syneos Health?

Syneos Health currently has 6 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SYNH, but not buy more shares or sell existing shares.
View the latest ratings for SYNH.

What other companies compete with Syneos Health?

How do I contact Syneos Health's investor relations team?

Syneos Health's physical mailing address is 1030 Sync Street, Morrisville NC, 27560. The company's listed phone number is (919) 876-9300 and its investor relations email address is [email protected] The official website for Syneos Health is www.syneoshealth.com. Learn More about contacing Syneos Health investor relations.